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ABSTRACT 
Objective: To synthesize structurally distinct N-alkyl/aryl-2-aryl indol-3yl-glyoxylamides to evaluate their anticancer activity on Murine double 
minutes-2(MDM2) receptor bind p53 and Pheripheral benzodiazepine receptor (PBR) protein. 
Methods: A series of new appropriately N-alkyl/aryl-2-aryl indol-3-yl glyoxylamides (2a-h), were synthesized by the reaction of 2-arylindoles, 
oxalyl chloride and different amines in one pot reaction. Structure of all the new compounds were elucidated by spectral analysis and evaluated in 
silico docking study with MDM2 receptor bind p53 and PBR protein. 
Results: Among all the tested compounds, the 2-[2-(4-chlorophenyl)-1H-indol-3-yl]-2-oxo-N-propylacetamide (2e) showed high binding affinity on 
MDM2 receptor bind p53 protein. While remaining, the 2-(5-chloro-2-phenyl-1H-indol-3-yl)-N-(2,4-dimethylphenyl)-2-oxoacetamide (2a), N-(4-
fluorophenyl)-2-[2-(4-methylphenyl)-1H-indol-3-yl]-2-oxoacetamide (2b) and 2-[2-(4-methylphenyl)-1H-indol-3-yl]-2-oxoacetamide (2c) were 
shown comparably good binding affinity on PBR protein. 
Conclusion: The Docking study of newly synthesized compounds revealed that the N-alkyl/aryl-2-aryl indol-3yl-glyoxylamides could be a very 
useful scaffold for anticancer therapy particularly on MDM2 receptor bind p53 and PBR protein. 
Keywords: N-alkyl/aryl-2-aryl indol-3-yl glyoxylamides; Oxalyl chloride; MDM2-p53: PBR; Docking; Lipinski rule. 
 
INTRODUCTION  
Design and synthesis of different small-molecule inhibitors that 
block the MDM2-p53 interaction has become an attractive strategy 
to activate p53 for the treatment of cancer and other human 
diseases. Recent advances in the design of small-molecule inhibitors 
of the MDM2-p53 interaction have gained much attention in recent 
years, and thus several compounds have reached advanced 
preclinical trials [1]. Hence, small-molecule such as various N,N-
dialkyl-(2-phenyl-1H-lindol-3-yl)glyoxylamides containing halogens 
in phenyl ring were reported to be highly selective for PBR ligands 
[2]. The indolyl glyoxylamide D-24851 (See Figure 1) has been 
reported to inhibit the growth of multidrug-resistant tumors both in 
vitro and in vivo [3]. Also various N-(indol-3-ylglyoxylyl)piperidines 
were reported to show high affinity against agonists of human 
GABA-A receptors [4]. Various N,N-dialkyl-[2-(4'-iodo- and 4'-
bromo-phenylindol-3-yl]glyoxylamides have also shown high 








Fig. 1: N-(pyrin-4-yl)-[1-(4-chlorobenzyl)-indol-3yl]-glyoxyl 
amide (D-24851) 
Various Indolyl glyoxylamides were also been investigated against 
several cancer cell lines, including multidrug resistance (MDR) cell 
lines [7-12]. Ferderico et al. also reported that N,N-disubstituted 
indol-3-ylglyoxylamides bearing different substitution represents 
potentially lead compounds for the treatment of anxiety disorders 
with high affinity for TSPO ligands [13].  
Antonio Da Settimo and coworkers have been identified that a 
various N-phenylindol-3-ylglyoxylohydrazides efficiently binds to 
brain benzodiazepine receptors [14]. Anticancer activity of various 
N-heterocyclic indolyl glyoxylamides were studied extensively by 
Penthala et al [15-18].  
The structure-activity relationships of various N-aryl(indol-3-
yl)glyoxamides exhibited potent anticancer activities [19]. 
Covering wide range of anticancer properties of various indolyl 
glyoxylamides, we felt it worthwhile to study the in silico docking of 
certain new derivatives N-alkyl/aryl-2-aryl indol-3-yl glyoxylamides 
2a-h to find out their ability to bind with MDM2 receptor bind p53 
and Pheripheral benzodiazepine receptor (PBR) protein. Hence in 
our continuing efforts to develop small molecules, that has been 
reported to posses anticancer property [20, 21], in this paper we 
highlighted the simple and more convenient synthesis of various 
new N-alkyl/aryl-2-aryl indol-3-yl glyoxylamide derivatives (2a-h) 
as a small-molecule inhibitors of MDM2-p53 and PBR protein. And 
the results obtained from these efforts with their molecular docking 
studies have been systematically studied and presented in this 
paper. 
MATERIALS AND METHODS 
Chemistry 
The chemicals used were that of analytical grade. Melting points 
were uncorrected, determined in open capillary. Purity of the 
compounds was checked by TLC on silica gel and compounds were 
purified by using column chromatography (pet ether/ethyl acetate 
8:2 v/v). 1H NMR spectra was recorded on a Bruker supercon FT 
NMR (400 MHz) spectrometer in CDCl3 or DMSO-d6 and TMS as an 
internal standard. The chemical shifts are expressed in δ units. Mass 
spectra was recorded on a JEOL SX 102/DA-6000 (10 kV) FAB mass 
spectrometer. The various 2-phenylindoles (1a-d) were synthesized 
following the literature method [14]. 
Typical procedure for the synthesis of 2-(5-chloro-2-phenyl-1H-
indol-3-yl)-N-(2,4-dimethylphenyl)-2-oxoacetamide 2a. 
To a partially dissolved solution of 5-chloro-2-phenyl-1H-indole (1 g, 
43 mmol) in anhydrous ether (30 ml) at 0 oC was added oxalyl 
chloride drop wise (0.53 mL, 43 mmol) and the mixture was stirred 
for 1 hr. The 2,4-dimethyl aniline (0.70 mL, 5.6 mmol) in anhydrous 
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ether (5ml) was added drop wise slowly for 30 min into the reaction 
mixture under constant stirring. After the completion of the reaction 
as indicated by TLC (ethyl acetate/pet ether 8:2 v/v), the reaction 
mass was then quenched with water and extracted with ethyl 
acetate and dried over anhydrous NaSO4. The crude product 2a was 
then purified by column chromatography on silica gel (pet 
ether/ethyl acetate 8:2 v/v). The yield 80% of product was obtained 





1H NMR(300 MHz, DMSO-d6): δ = 12.64(s, 1H), 8.12(s, 2.4 Hz, 1H), 
7.67(s, 1H), 7.51(d, J =4.8 Hz, 2H), 7.44-7.43(m, 3H), 7.37-7.31(m, 
2H), 7.08-7.02(m, 3H), 2.49(s, 3H), 2.27(s, 3H). 13C NMR (300 MHz, 
DMSO-d6) δ =186.8, 164.6, 158.5, 148.6, 135.2, 134.4, 132.4, 132.2, 
131.4, 130.9, 130.7, 129.6, 128.6, 126.9, 126.6, 124.3, 123.4, 119.9, 
116.2, 113.6, 108.7, 20.4, 17.4. MS: m/z=403.2 (M+1), 405.2 (M+2). 
N-(4-fluorophenyl)-2-[2-(4-methylphenyl)-1H-indol-3-yl]-2-
oxoacetamide (2b) 
1H NMR(400 MHz, DMSO-d6): δ = 12.42(s, 1H), 8.15(d, J=7.32 Hz, 
1H), 7.86-7.91(m, 3H), 7.43-7.51(m, 3H), 7.33-7.26(m, 6H), 
2.21(s,3H). 13C NMR (300 MHz, DMSO-d6) δ = 186.4, 164.6, 158.4, 
157.2, 148.3, 138.9, 135.8, 134.3, 134.0, 129.3, 128.3, 128.5, 127.3, 
123.4, 122.4, 122.2, 121.1, 121.3, 115.2, 115.0, 114.7, 112.0, 20.7. 
MS: m/z=371.0 (M-1). 
2-[2-(4-methylphenyl)-1H-indol-3-yl]-2-oxoacetamide (2c). 
1H-NMR(400 MHz, DMSO-d6): δ = 12.28(s, 1H), 8.05(d, J=8 Hz, 1H), 
7.95(s, 1H), 7.48(m, 4H), 7.25(m, 4H), 2.39(s,3H). 13C NMR (300 MHz, 
DMSO-d6) δ = 187.7, 168.6, 147.0, 138.8, 135.7, 129.5, 128,6, 127.4, 




1H NMR(400 MHz, DMSO-d6): δ = 12.65(s, 1H), 8.1(d, J=2 Hz, 1H), 
7.68-7.66(m, 2H), 7.55-7.47(m, 4H), 7.34-7.32(m, 2H), 6.86-7.17(m, 
3H), 2.1-2.29(m, 6H). 13C NMR (300 MHz, DMSO-d6) δ = 164.6, 158.4, 
148.8, 135.2, 134.7, 134.6, 134.5, 134.3, 130.9, 130.1, 129.9, 129.5, 
128.9, 128,5, 128.3, 126.9, 126.7, 125.1, 123.4, 120.0, 113.8, 108.7, 
20.5, 17.5. MS: m/z=403.0 (M+1), 404.0 (M+2). 
2-[2-(4-chlorophenyl)-1H-indol-3-yl]-2-oxo-N-propylacetamide (2e). 
1H NMR(400 MHz, DMSO-d6): δ =12.42(s, 1H), 8.50(t, J=6.4 Hz, 1H), 
8.07(m,1H), 7.58(m, 4H), 7.49(t, J= 5.6Hz, 1H), 7.29(m, 2H), 2.77(q, 
J= 7.2, 13.2 Hz, 2H), 1.28(q, J= 7.2, 14.4 Hz, 2H), 0.79(t, J=7.2 Hz, 3H). 
13C NMR (300 MHz, DMSO-d6) δ = 188.0, 166.8, 146.2, 136.2, 134.6, 
131.8, 130.7, 128.5, 127.7, 123.9, 122.8, 121.4, 112.4, 110.0, 22.1, 
11.9. MS: m/z= 341(M+1), 342(M+2). 
2-[2-(4-chlorophenyl)-1H-indol-3-yl]-2-oxo-N-(tetrahydro-2H-pyran-4-
yl)acetamide (2f). 
1H NMR(400 MHz, DMSO-d6): δ = 12.59(s, 1H), 8.15(d, J= 7.2 Hz, 1H), 
7.63(s, 4H), 7.51(d, J= 7.6 Hz, 1H), 7.31(m, 2H), 3.41(t, J= 4.8 Hz, 4H), 
3.221(t, J= 4 Hz, 2H), 3.11(t, J= 4.4 Hz, 2H). 13C NMR (300 MHz, 
DMSO-d6) δ =187.0, 166.1, 146.7, 136.2, 135.1, 132.4, 129,8, 127,0, 
124.2, 123.2, 121.5, 112.6, 110.4, 66.0, 65.7, 45.9. MS: m/z= 
369(M+1), 370(M+2). 
N-butyl-2-[2-(4-chlorophenyl)-1H-indol-3-yl]-2-oxoacetamide (2g). 
1H NMR(300 MHz, DMSO-d6): δ =12.31(bs, 1H), 8.45(t, J= 5.4 Hz, 1H), 
8.08(m, 1H), 7.56(m, 5H), 7.26(m, 2H), 2.50(m, 2H), 1.19(m, 4H), 0.84(q, 
J= 6, 12 Hz, 3H). 13C NMR (300 MHz, DMSO-d6) δ =187.5, 166.3, 145.7, 
135.7, 134.1, 131.3, 130.2, 128.0, 127.2, 123.3, 122.2, 120.8, 111.9, 109.5, 
37.9, 30.3, 19.5, 13.5. MS: m/z= 255(M+1), 256(M+2). 
2-[2-(4-bromophenyl)-1H-indol-3-yl]-N-butyl-2-oxoacetamide (2h). 
1H NMR(400 MHz, CDCl3): δ =8.77(s, 1H), 8.18(t, J= 2.56, 1H), 7.53(d, 
J= 8.2 Hz 2H), 7.34(m, 5H), 6.85(s, 1H), 3.18(q, J= 6.6, 13.5 Hz, 2H), 
1.47(m, 2H), 1.34(q, J= 6.8, 14.9 Hz, 2H), 0.95(d, J= 7.2 Hz, 3H). 13C 
NMR (300 MHz, DMSO-d6) δ = 187.5, 166.2, 145.7, 135.7, 131.5, 
130.9, 130.5, 127.2, 123.4, 122.8, 122.2, 120.8, 111.9, 109.5, 37.9, 
30.3, 19.5, 13.5. MS: m/z=399.0 (M+), 402.0 (M+2). 
In silico molecular docking studies 
Pharmacophore Analysis 
The synthesized N-alkyl/aryl-2-aryl indol-3-yl glyoxylamides 
(2a-h) compounds were used for molecular and biochemical 
characterization. The pharamcophore analyses of these 
compounds were studied with respect to chloro, bromo, methyl 
and fluro substituents. The chemical structures of these new 
compounds were drawn using ChemDraw Ultra 8.0. The 
Quantitative structure activity relationship (QSAR) was used to 
characterize the properties of each functionally derived 
compound with calculated molecular properties which help to 
understand the properties of inhibitors. 
Identification of Protein structure 
The crystal structure of MDM2 receptor bind p53 tumor 
suppressor protein (PDB ID: 1RV1) shows over expression in 
transcriptional inhibition and impairs the p53 function, this 
characteristic shows inhibition of further downstream pathways 
[23]. Another protein peripheral benzodiazepine receptor (PBR) 
(PDBID: 1EQ1) [24] helps translocation of cholesterol and 
porphyrin across the mitochondrial outer membrane and helps 
for steroid biosynthesis [25], cellular respiration [26], 
proliferation [27] and apoptosis [28]. The 3D integration of X-
ray crystal structures with stereochemical activity were 
predicted using structural analysis and verification server 
(SAVS). The new active sites of MDM2 receptor bind p53 and 
PBR with nonpolar integration of valid amino acids were 
predicted using Q-site finder 
[www.bioinformatics.leeds.ac.uk/qsitefinder]. The activity of 3D 
structure is assumed as a ligand binding site and the whole 
protein structure itself is used as ligand binding site. The 
hydrophobic nature of active site amino acids were calculated 
using RMSA shows geometry accuracy of target protein 
structures. The resultant protein structures helps for rigid 
docking against the synthetic molecules (2a-h). The docking 
study was performed using AutoDockTools (ADT) v 1.5.4 and 
AutoDock v 4.2 program to create grid maps of different grid 
points for covering ligand binding pockets such as active site 
amino acids. Using molecular modeling and simulation 
algorithms such as Lamarckian genetic algorithm helps for 
molecular simulation and docking. Different molecular 
simulation parameters were used in grid point such as 80 x 80 x 
80 and docking. The parameters such as population size of 150, 
the mutation rate of 0.02 and crossover rate of 0.8 were fixed 
accordingly. Secondly, the Simulations were performed up to 2.5 
million energy and the evaluations were maximum at 27000 
generations. Each simulation was carried about 10 times which 
ultimately yielded 10 docked conformations. From this, the 
lowest energy conformations were regarded as the best binding 
conformations. In the end, the reverse validation processes 
ensured the identified hits that fitted with generated 
pharmacophore models and active sites of both targets. Since all 
the parameters were required for molecular docking and 
pharmacophore mapping, they were consequently fixed and used 
in regular process. 
RESULTS AND DISCUSSION 
Various N-alkyl/aryl-2-aryl indol-3-yl glyoxylamides (2a-h) (Scheme 1 
and Table 1) were synthesized via one pot multicomponent reaction. 
The target compounds were prepared by  reacting various 
appropriately substituted 2-arylindoles (1a-d) with oxalyl chloride 
and different amines in presence of anhydrous ether at 0 oC in one 
pot by suitable modification of the reaction reported in the literature 
[6]. 
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R11. (COCl)2, anhydrous ether
2. Amine, anhydrous ether
                0 oC
R = H, Cl, Br, Me







Scheme 1: Synthesis of N-alkyl/aryl-2-aryl indol-3-yl glyoxylamids (2a-h). 
Table 1: Physical properties of N-alkyl/aryl-2-aryl indol-3-yl glyoxylamids (2a-h) 
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a Isolated yields. 
 
Molecular docking studies 
A series of N-alkyl/aryl-2-aryl indol-3-yl glyoxylamide derivatives 
(2a-h) with chemical portion plays an important role in the 
interaction with MDM2 receptor bind p53 and PBR proteins. The 
Pharmacophore properties of each descriptor were predicted using 
Hyperchem 7.5 Professional. Each functional groups shows lower 
energy direction of atom position.  
The QSAR properties of synthetic compounds were hailed to relate 
the structural descriptors of receptors with physicochemical 
properties and biological activities. The Lipinski rule is applied on 
the selected molecules (2a-h) are LogP (the logarithm of octanol/ 
water partition coefficient), molecular weight, and the number of 
hydrogen bond acceptors. Most “drug- like” molecules have logP ≤ 5, 
molecular weight ≤ 500, number of hydrogen bond acceptors ≤ 10, 
and number of hydrogen bond donor’s ≤ 5.  
Molecular violations are occurred any of these properties is shows 
problem with bioavailability.  
The Lipinski’s rule of five parameters and total polar surface area 
(TPSA), which has shown to correlate with drug absorption, were 
obtained by using the Molinspiration program (Table 2). 
 
Table 2: Lipinski rule of N-alkyl/aryl-2-aryl indol-3-yl glyoxylamides (2a-h) 
Ligand LogP TPSA nAtoms MW nON nOHNH nrotb MV nviolations 
2a 5.566 61.96 29.0 402.881 4 2 4 352.865 1 
2b 4.699 61.96 28 372.399 4 2 4 327.7 0 
2c 2.464 75.956 21.0 278.311 4 3 3 250.246 0 
2d 5.59 61.96 29.0 402.881 4 2 4 352.865 1 
2e 3.946 61.96 24.0 340.81 4 2 5 298.499 0 
2f 3.158 62.405 26.0 368.82 5 1 3 314.066 0 
2g 4.505 61.96 25.0 354.837 4 2 6 315.301 0 
2h 4.636 60.96 25.0 399.288 4 2 6 319.651 0 
LogP=logarithm of the octanol/water partition coefficient; TPSA=topological polar surface area; nAtoms=number of atoms; MW=molecular weight; 
nON=number of hydrogen bond acceptors; nOHNH = number of hydrogen bond donors; nrotb=number of rotatable bonds; MV=molecular volume; 
nviolations=number of violations of the Lipinski’s rule of five..  
The active crystal structures of MDM2 receptor bind p53 tumor 
suppressor protein and peripheral benzodiazepine receptor structure 
(PBR) was interacted with pharmacophores N-alkyl/aryl-2-aryl indol-3-
yl glyoxylamides (2a-h) using molecular docking. The potential binding 
surface were calculated and a cavity of 1713.3 Å was observed close to 
Lys51, Leu 54, Phe55, Gly58, Gln59, Ile61, Met62, Gln72, His73, Val93, 
 His 96 and Tyr100 is predicted in 1RV1 and the resultant protein is 
potentially used as a drug binding sites. The PBR protein has active site 
surface of 514.8 Å is near to Thr22, Ala56, Ser59, Gln78, Asn82, Thr114, 
Gln117, Ser119, Ile141, Asp147 and Gln156. The protein structure such 
as MDM2 receptor (A chain) has more ligand binding sites which are 
predicted based on non polar interaction with the ligand molecule 
 
 Table 3: Molecular Docking study of 1RV1 protein complex with N-alkyl/aryl-2-aryl indol-3-yl glyoxylamides (2a-h) 






RMSD Amino acids 
2a 2 -25.4927 109.877 -2.5 99.06 Lys51 
2b 2 -22.7939 111.625 -1.85 95.78 Phe55, Gln59 
2c 2 -25.6669 82.991 0.123 79.51 Gln72, Tyr100 
2d 2 -6.73602 75.711 -2.5 28.56 His96 
2e 3 -17.2424 93.201 0.134 12.86 Lys51, Gln59 
2f 2 -6.5768 86.975 0.177 95.13 Val93, His96 
2g 1 -16.2813 104.185 0.134 98.37 Leu54 
2h 1 -8.02555 102.343 2.45 8.44 Tyr100 
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Fig. 2: Docking images of selected compounds with p53 showing binding of compound 2d with His96 (2H bonds) and compound 2e with 
Lys51, Gln59 (3H bonds). The blue colored dashed line denote the hydrogen bonds 
 
Fig. 3: Docking images of selected compounds with 1EQ1 showing binding of compound 2a with Ala56, Ser59, Asp147 (3H bonds) and 
compound 2b with Gln78, Asn82 (3H bonds). The blue colored dashed line denote the hydrogen bonds 
 
The docking results are calculated according to binding energy and 
RMSD values. The docking score of both 1RV1 and 1EQ1 proteins were 
mention in Table 3 and 4. 2D structure of all new ligands 2a-h were 
converted into energy minimized 3D structures and were then used for 
in silico protein-ligand docking. The docking of MDM2 receptor bind p53 
tumor suppressor protein with newly synthesized ligands 2a-h 
exhibited well established bonds with one or more amino acids in the 
receptor active pocket. Figure 2 shows the docked images of selected 
candidate ligands 2-[2-(4-chlorophenyl)-1H-indol-3-yl]-N-(2,4-
dimethylphenyl)-2-oxoacetamide (2d) and 2-[2-(4-chlorophenyl)-1H-
indol-3-yl]-2-oxo-N-propylacetamide (2e). Table 3 shows the binding 
energy and inhibition constant of eight compounds. In silico studies 
revealed that all the synthesized molecules showed good binding energy 
toward the target protein ranging from -6.57 to -25.66 kcal/mol. The 
compound 2e has shown 3 hydrogen bonding interaction with active 
site amino acids Lys51 and Gln59 having energy -17.2424 kcal/mol 
exhibiting promising interaction on MDM2 receptor bind p53 protein to 
control the transcription regulation. The other molecules such as 2a-d 
and 2f have lesser binding affinity on target MDM2 receptor bind p53 
protein 
Similarly docking study was performed on PBR receptor (1EQ1) 
with N-alkyl/aryl-2-aryl indol-3-yl glyoxylamides derivatives (Table 
4). The ligands 2a-c forms 3 hydrogen bonding interaction with 
active site amino acid Ala56, Ser59, Asp147, Gln78, Asn82, Ser119, 
and Ile141 having binding energy -8.8370, -15.219 and -20.597 
kcal/mol respectively, indicates potent inhibitor of PBR. Figure 3 
shows the docked images of selected candidate ligands 2-(5-chloro-
2-phenyl-1H-indol-3-yl)-N-(2,4-dimethylphenyl)-2-oxoacetamide 
(2a) and N-(4-fluorophenyl)-2-[2-(4-methylphenyl)-1H-indol-3-yl]-
2-oxoacetamide (2b). Other structural compounds such as 2d and 
2h have relatively no interaction with target protein and hence can’t 
be considered as an inhibitor of PBR. 









RMSD Amino acids 
2a 3 -8.8370 58.876 -2.69 2.21 Ala56, er59,Asp147 
2b 3 -15.219 87.520 -0.13 4.33 Gln78, Asn82 
2c 3 -20.597 16.016 -2.92 10.52 Ser119, Ile141 
2d - - - - - - 
2e 1 -3.025 2.660 -0.11 2.812 Thr114 
2f 2 -10.136 70.341 0.177 73.26 Thr22, Gln156 
2g 2 -5.1613 44.317 0.296 46.321 Thr114, Gln117 
2h - - - - - - 
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CONCLUSION 
Various structurally distinct N-alkyl/aryl-2-aryl indol-3-yl glyoxylamides 
(2a-h) have been conveniently synthesized and characterized. The in 
silico docking study of N-alkyl/aryl-2-aryl indol-3-yl glyoxylamides were 
revealed that the compound 2e found to bind efficiently with 1RV1 
protein whereas, compounds 2a, 2b, 2c efficiently binds with 1EQ1 
protein with lesser binding energy in comparison with remaining 
compounds. Hence this study will further widen the scope for the 
development of still similar new N-alkyl/aryl-2-aryl indol-3-yl 
glyoxylamides as possible potential anticancer agents. 
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